Crémieux
Crémieux
ADA-0,92%
Eli Lilly just showed that you can lose tons of fat while barely losing any muscle using their activin type-II receptor inhibitor, bimagrumab. We are approaching a golden era of weight loss, where everyone can easily be muscular and skinny. Prepare for hordes of hot Americans.
Gallery 1
The semaglutide-only weight loss results also speak against the lie that GLP-1RAs cause excess lean mass loss, as the proportion lost was comparable to typical non-GLP-1RA weight loss. To learn more, check out the update I just made on this article:
Reporting on this result from the ADA 2025 conference:
Egan Peltan
Egan Peltan
Can less weight loss be better weight loss? This morning at ADA, Eli Lilly released data on the Believe Phase 2b study of Bimagrumab in combination with a GLP-1 (Semaglutide) The goal: lose only fat Approach: anorectic + anabolic
@subtlechemism Nope.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@cmoncanes There's never been good evidence for them. It just doesn't gomd up on closer inspection.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@AnnieTyzak Eye issues? Never supported with strong evidence.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@elonmusk And it seems like consumers will have options, too. Multiple other companies are close to their own versions of this product: We live in amazing times!
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
@AZchilly Then I'd say you didn't read the article. Here's a helpful thread with human rather than non-human primate results.
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
Fontetwitter
8,12 mil
0
O conteúdo apresentado nesta página é fornecido por terceiros. Salvo indicação em contrário, a OKX não é o autor dos artigos citados e não reivindica quaisquer direitos de autor nos materiais. O conteúdo é fornecido apenas para fins informativos e não representa a opinião da OKX. Não se destina a ser um endosso de qualquer tipo e não deve ser considerado conselho de investimento ou uma solicitação para comprar ou vender ativos digitais. Na medida em que a IA generativa é utilizada para fornecer resumos ou outras informações, esse mesmo conteúdo gerado por IA pode ser impreciso ou inconsistente. Leia o artigo associado para obter mais detalhes e informações. A OKX não é responsável pelo conteúdo apresentado nos sites de terceiros. As detenções de ativos digitais, incluindo criptomoedas estáveis e NFTs, envolvem um nível de risco elevado e podem sofrer grandes flutuações. Deve considerar cuidadosamente se o trading ou a detenção de ativos digitais é adequado para si à luz da sua condição financeira.